Table of Contents Table of Contents
Previous Page  774 / 812 Next Page
Information
Show Menu
Previous Page 774 / 812 Next Page
Page Background

S770

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

EV1321

Therapeutic attitudes and clinical

global impression: A 2-year follow-up

study of 33 outpatients with a mental

disorder in treatment with

paliperidone palmitate

M.D. Perez Lopez

, M. Soto laguna , J. Prados Gomez ,

I. Zarranz Herrera Oria , R. Perez Asenjo , S. Bola˜no Mendoza ,

M. Fernandez Torrija Daza , P. Gonzalez Rivera ,

B. Herrejon Teodoro

Hospital Provincial de Toledo, Psiquiatria, Toledo, Spain

Corresponding author.

Introduction

Maintaining antipsychotic therapy in mental dis-

order is important in preventing relapse, rehospitalization, and

suicide. Lack of awareness of illness may be a leading cause for non-

adherence. Long-acting depot can prevent non- adherence and thus

potentially contribute to better patient outcomes.

Objective

The aim of this prospective, observational, non

interventional 2-year-long study is to assess severity and post-

intervention changes and attitudes toward medication of a group

of patients treated paliperidone palmitate (PP).

Methods

Thirty-three outpatients stabilised with PP during the

last 24 months. Inclusion criteria were: patients’ age (> 18 years),

a diagnosis of schizophrenia, bipolar disorder, schizoaffective dis-

order stabilised during the last 12 months with PP, without a

diagnostics from axis I or II (except for nicotine of caffeine)

and able to sign the inform consent. Data collected: general

sociodemographic and clinical data (age, sex, level of education,

socioeconomic situation, family support, psychiatric diagnosis,

years of evolution, use/abuse of substances, treatment, previous

and later number of hospitalisations. Evaluations included disease

severity (Clinical Global Impression-Severity (CGI-S) and Drug Atti-

tude Inventory, (DAI)).

Results

Thirty-threeoutpatientswere followed during 24months

[mean dose 132,58 (44,4) mg], 75,8% were men, age 45,05 years

old, 87,8% with a diagnoses of paranoid schizophrenia. Antipsy-

chotic monotherapy increased over the time with PP. Significant

improvements were observed on both Clinical Global Impression

and Drug Attitude Inventory. The number of rehospitalizations and

mean stays decreased from the beginning until the end of these 24

months.

Conclusions

Our results suggest an improvement in the patient’s

clinical vision and attitude towards medication with long-acting

depot.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2306

EV1322

DECIDE Study: Effectiveness of shared

decision-making in treatment

planning at discharge of inpatient

with schizophrenia. Experience after

20 months of the study

J. Pérez Revuelta

1 ,

, J.M. Pascual Pa˜no

2

, I. Lara Ruiz-Granados

3

,

F. Gonzalez Saiz

2

, C. Rodriguez Gomez

2

, J.M. Mongil San Juan

2

,

M. Ayerbe de Celis

2

, M. Pavon Garcia

2

, J. Mestre Morales

2

,

M.J. Garcia del Rio

2

, R. Guerrero Vida

2

, J.M. Villagran Moreno

2

1

Servicio Andaluz Salud, Fundacion Biomedica Cadiz, Clinical

Management Unit of Mental Health, Jerez de la Frontera, Spain

2

Servicio Andaluz Salud, Clinical Management Unit of Mental Health,

Jerez de la Frontera, Spain

3

Servicio Andaluz Salud, Macarena Clinical Management Unit of

Mental Health, Sevilla, Spain

Corresponding author.

Introduction

Shared decision-making denotes a structured pro-

cess that encourages full participation by patient and provider

in making complex medical decisions. There has been extensive

and growing interest in its application to long-term illnesses but

surprisingly not in severe psychiatric disorders, such as schizophre-

nia. However, the great majority of schizophrenics are capable of

understanding treatment choices and making rational decisions.

Although the main justification for shared decision-making is ethi-

cal, several randomized controlled trials support its effectiveness in

improving the quality of decisions, but robust evidence in objective

health outcomes is needed.

Aims and objectives

Of the study: to demonstrate the effective-

ness, measured as treatment adherence and readmissions at 3, 6

and 12 months, of shared decision making in the choice of antipsy-

chotic treatment at discharge.

Of the oral presentation: to present the study design; to make an

interim report of the data obtained at the moment of the congress.

Methods

Randomized controlled trial, prospective, two parallel

groups, not masked, comparing two interventions (shared deci-

sion making and treatment as usual). Study population: Inpatients

diagnosed of schizophrenia and schizoaffective disorders (ICD-

10/DSM-IV-R: F20 y F25) at Adult Acute Hospitalization Unit at

Jerez General Hospital.

Results

Currently in the recruiting phase with 55 patients

included in the study. An interim analysis of at least half of the

target sample size.

Conclusions

We will show the study design and decision tools

employed. Conclusions in relation to the effectiveness (adherence

and readmissions) and subjective perception.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2307

EV1323

DECIDE Study: Antipsychotic

treatment profile. Comparison of

antipsychotic polytherapy in patients

discharged after acute episode of

UHSM, taking decisions shared vs.

usual care strategies

J. Pérez Revuelta

1 ,

, M. Ayerbe de Celis

2

, J.M. Mongil San Juan

2

,

C. Rodriguez Gomez

2

, J.M. Villagran Moreno

2

1

San Fernando, Spain

2

Servicio Andaluz Salud, Clinical Management Unit of Mental Health,

Jerez de la Frontera, Spain

Corresponding author.

Introduction

Shared decision-making denotes a structured pro-

cess that encourages full participation by patient and provider

in making complex medical decisions. Although the main justifi-

cation for shared decision-making is ethical, several randomized

controlled trials support its effectiveness in improving the quality

of decisions, but robust evidence in objective health outcomes is

needed.

Aims

Analyze the degree of antipsychotic politherapy or

monotherapy in patients discharged after their inclusion in the

study and randomized to Share Decision-Making or Treat as Usual.

Present preliminary conclusions after 20 months of follow-up.

Methods

Randomized controlled trial, prospective, two parallel

groups, not masked, comparing two interventions (shared decision

making and treatment as usual). Previous antipsychotic treatment

is collected by interviewing patient and family and as included in

digital history and health card, discharge and reviews conducted at

3, 6 and 12 months.

Results

Interim analysis shows there are no differences between

groups (SDM and TaU) before intervention, we note the following

results: